|
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
|
|
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia
|
|
Rituximab intolerance in patients with Waldenstrom's macroglobulinaemia
|
|
MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinemia
|
|
LLF - Waldenstrom's Macroglobulinemia Facts
|
|
Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia
|
|
How I treat Waldenstrom macroglobulinemia
|
|
Survival outcomes of secondary cancers in patients with Waldenström Macroglobulinemia: An analysis of the SEER database
|
|
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
|
|
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells
|
|
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia
|
|
Extramedullary Waldenström macroglobulinemia
|
|
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|
|
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database
|
|
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database
|
|
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells
|
